Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones

Leukemia (2003) 17, 634-635. doi:10.1038/sj.leu.2402842

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2003-03, Vol.17 (3), p.634-635
Hauptverfasser:	Chee, Y L, Vickers, M A, Stevenson, D, Holyoake, T L, Culligan, D J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Cancer Research Clone Cells - pathology Critical Care Medicine Drug toxicity and drugs side effects treatment Fatal Outcome Hematology Humans Imatinib Imatinib Mesylate Intensive Internal Medicine Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Medical sciences Medicine Medicine & Public Health Miscellaneous (drug allergy, mutagens, teratogens...) Myelodysplastic syndrome Myelodysplastic Syndromes - chemically induced Myelodysplastic Syndromes - pathology Neoplasms, Second Primary - chemically induced Neoplasms, Second Primary - pathology Oncology Pharmacology. Drug treatments Philadelphia Chromosome Piperazines - adverse effects Piperazines - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use spotlight-correspondence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!